CN108338983B - 乙酰华蟾毒精在制备治疗肿瘤药物中的应用 - Google Patents
乙酰华蟾毒精在制备治疗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN108338983B CN108338983B CN201810059566.XA CN201810059566A CN108338983B CN 108338983 B CN108338983 B CN 108338983B CN 201810059566 A CN201810059566 A CN 201810059566A CN 108338983 B CN108338983 B CN 108338983B
- Authority
- CN
- China
- Prior art keywords
- cinobufagin
- cells
- acetyl
- acetocinobufagin
- tnbc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0021—Oxiranes at position 14(15)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010644562.5A CN112159453B (zh) | 2018-01-22 | 2018-01-22 | 乙酰华蟾毒精及其在制备治疗肿瘤药物中的应用 |
CN201810059566.XA CN108338983B (zh) | 2018-01-22 | 2018-01-22 | 乙酰华蟾毒精在制备治疗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810059566.XA CN108338983B (zh) | 2018-01-22 | 2018-01-22 | 乙酰华蟾毒精在制备治疗肿瘤药物中的应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010644562.5A Division CN112159453B (zh) | 2018-01-22 | 2018-01-22 | 乙酰华蟾毒精及其在制备治疗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108338983A CN108338983A (zh) | 2018-07-31 |
CN108338983B true CN108338983B (zh) | 2020-08-11 |
Family
ID=62961152
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010644562.5A Active CN112159453B (zh) | 2018-01-22 | 2018-01-22 | 乙酰华蟾毒精及其在制备治疗肿瘤药物中的应用 |
CN201810059566.XA Active CN108338983B (zh) | 2018-01-22 | 2018-01-22 | 乙酰华蟾毒精在制备治疗肿瘤药物中的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010644562.5A Active CN112159453B (zh) | 2018-01-22 | 2018-01-22 | 乙酰华蟾毒精及其在制备治疗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN112159453B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117695293A (zh) * | 2021-09-08 | 2024-03-15 | 长沙欧邦生物科技有限公司 | 蟾毒配基类成分的降解物的制备方法和应用 |
CN115400134B (zh) * | 2022-09-30 | 2023-06-16 | 浙江省人民医院 | 用于治疗甲状腺未分化癌的mcl-1抑制剂及其应用 |
CN115737594A (zh) * | 2022-11-08 | 2023-03-07 | 湖南万欧科技有限公司 | 一种负载华蟾毒精的仿生普鲁士蓝纳米复合材料及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110076278A1 (en) * | 2005-08-02 | 2011-03-31 | Mehran Khodadoust | Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders |
-
2018
- 2018-01-22 CN CN202010644562.5A patent/CN112159453B/zh active Active
- 2018-01-22 CN CN201810059566.XA patent/CN108338983B/zh active Active
Non-Patent Citations (1)
Title |
---|
曹珍等.远华蟾毒精对小鼠乳腺癌细胞侵袭的抑制作用及机制.《山东医药》.2017, * |
Also Published As
Publication number | Publication date |
---|---|
CN112159453B (zh) | 2021-09-17 |
CN108338983A (zh) | 2018-07-31 |
CN112159453A (zh) | 2021-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gu et al. | Roles of toll-like receptors: From inflammation to lung cancer progression | |
Mei et al. | Anticancer and anti-inflammatory properties of mangiferin: A review of its molecular mechanisms | |
CN108338983B (zh) | 乙酰华蟾毒精在制备治疗肿瘤药物中的应用 | |
Tung et al. | Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor | |
Li et al. | A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis | |
JP2011527291A5 (zh) | ||
Zheng et al. | Optimization of the process for purifying icariin from Herba Epimedii by macroporous resin and the regulatory role of icariin in the tumor immune microenvironment | |
Ni et al. | Trichosanthes kirilowii fruits inhibit non-small cell lung cancer cell growth through mitotic cell-cycle arrest | |
Cheng et al. | Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer | |
CN103191095B (zh) | 一种stat3信号通路小分子抑制剂及其在制备抗肿瘤药物中的应用 | |
Fan et al. | Protective effects of recombinant lactoferrin with different iron saturations on enteritis injury in young mice | |
Zhong et al. | DL-methionine and DL-methionyl-DL-methionine increase intestinal development and activate Wnt/β-catenin signaling activity in domestic pigeons (Columba livia) | |
Xu et al. | Targeting tumor microenvironment: Effects of chinese herbal formulae on macrophage‐mediated lung cancer in mice | |
Wang et al. | Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of Scutellaria baicalensis and Qing-Shu-Yi-Qi-Tang | |
Agiorgiti et al. | Cytotoxic effect, antitumour activity and toxicity of organotin derivatives with ortho-or para-hydroxy-benzoic acids | |
Chen et al. | Sini decoction inhibits tumor progression and enhances the anti-tumor immune response in a murine model of colon cancer | |
US20130164382A1 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
Wu et al. | Trichinella spiralis muscle larvae excretory/secretory products trigger apoptosis and S-phase arrest of the non-small-cell lung cancer line A549 | |
CN102688489B (zh) | 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
CN108295085B (zh) | 原薯蓣皂苷在制备抗耐药性骨肉瘤药物中的应用 | |
Li et al. | Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19 | |
CN102961374B (zh) | 一种化合物的应用以及stat3抑制剂 | |
CN105769863B (zh) | 替拉那韦在抗癌症药物中的应用及抗癌症药物 | |
Shin et al. | Lucidumol A, Purified Directly from Ganoderma lucidum, Exhibits Anticancer Effect and Cellular Inflammatory Response in Colorectal Cancer | |
CN114010789A (zh) | 蟾蜍甾烯类化合物在制备治疗egfr和/或stat3驱动疾病的药物或保健品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220114 Address after: 325036 Wenzhou City National University Science Park incubator, No. 38 Dongfang South Road, Ouhai Economic Development Zone, Wenzhou, Zhejiang Patentee after: WENZHOU MEDICAL University Address before: 325000 Wenzhou City National University Science Park incubator, No. 38 Dongfang South Road, Ouhai Economic Development Zone, Wenzhou, Zhejiang Patentee before: WENZHOU MEDICAL University Patentee before: ZHEJIANG YIHUI BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220608 Address after: 325000 room 2020, building a, North District, Gene Medicine Valley, Ouhai District, Wenzhou City, Zhejiang Province Patentee after: Zhejiang Kunlong Technology Co.,Ltd. Address before: 325036 Wenzhou City National University Science Park incubator, No. 38 Dongfang South Road, Ouhai Economic Development Zone, Wenzhou, Zhejiang Patentee before: WENZHOU MEDICAL University |